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Abstract: Lennox–Gastaut syndrome (LGS) is a rare but debilitating pediatric epileptic 
encephalopathy characterized by multiple intractable seizure types. Treatment of LGS is 
challenging because of the small number of antiepileptic drugs (AEDs) which are effective 
for this syndrome, as well as the need for polytherapy in the majority of patients. This review 
focuses on the treatment of LGS with rufinamide, a recently approved third-generation AED 
with reported efficacy as adjunctive therapy for LGS. All relevant papers identified through a 
PubMed search on the treatment of LGS with rufinamide were reviewed. To date, the literature 
suggests improvements in seizure frequency for pediatric patients with LGS on rufinamide. 
Rufinamide appears to be especially effective for atonic or drop attack seizures. Rufinamide also 
displays a favorable adverse event profile compared with the older anticonvulsants, as well as a 
minimal number of drug interactions, making it a promising option for the adjunctive treatment 
of seizures associated with LGS.
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Introduction
Lennox–Gastaut syndrome (LGS) is an uncommon but refractory epileptic 
  encephalopathy of childhood, with a peak onset at 3–5 years of age.1–3 It is classified 
by the International League Against Epilepsy as a symptomatic generalized syndrome 
and requires a triad of clinical characteristics for diagnosis.4 First, patients exhibit an 
interictal slow spike-and wave pattern (less than 2.5 Hz) on the electroencephalogram 
with paroxysmal fast rhythms (10 Hz) during sleep. The second characteristic is 
multiple generalized seizure types. Tonic seizures (often during sleep), atonic or drop 
attack seizures, and atypical absence seizures are the most common types; however, 
patients may also exhibit myoclonic generalized tonic-clonic, partial absence, and 
unclassified seizures. The third characteristic is cognitive impairment, with severe 
mental retardation found in more than half of patients.1,4–6
LGS accounts for only 1%–4% of all childhood epilepsies, but is viewed as one 
of the most difficult epilepsies to control.4 In many cases the etiology is unknown, 
and the presentation of multiple seizure types often leads to antiepileptic drug (AED) 
polytherapy.7 The multidrug and high-dose regimens required increase the risk for drug 
interactions, thereby affecting adjunctive AED serum concentrations and increasing 
the risk of medication overdose or ineffective treatment. Moreover, most of the AEDs 
have intolerable adverse effects or can exacerbate different seizures which occur within 
LGS. Only a few AEDs have been shown to be effective for LGS.8 Even with AED 
polytherapy, the long-term prognosis is poor, with a persistence of epilepsy in more than Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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75% of patients.9 This incomplete seizure control often results 
in significant lifetime health care costs for the patient.10
A patient’s quality of life is very poor, with drop attacks 
being the most troubling presentation of LGS. These are 
the most physically damaging seizures, often causing head 
injuries due to falls.11 Therefore, many patients require close 
supervision, protective headgear, or confinement. A reduc-
tion in drop attacks is one of the most clinically significant 
outcomes for patients with LGS.12
The treatment goals for LGS are to provide the best seizure 
control possible using the fewest medications, while limiting the 
risk of adverse events.13,14 Currently, valproic acid is considered 
first-line therapy, and is considered effective for multiple seizure 
types in LGS; however, its use is not supported by controlled 
trials. Furthermore, the risk of life-threatening hepatotoxicity 
appears to be greater in children under two years of age, and 
valproate consequently tends to be avoided in this subgroup 
if other options are available.15 Topiramate, lamotrigine, and 
felbamate have demonstrated efficacy as adjunctive therapies in 
randomized,   placebo-controlled trials.16–18 Topiramate and lam-
otrigine are currently recommended as second-line therapy and 
have comparatively more favorable tolerability.15,19 Felbamate 
lacks sedative effects, but it also carries serious risks of aplastic 
anemia and hepatotoxicity which limit its use.19 Clobazam, a 
benzodiazepine with less sedative potential than other members 
of its class, is also a potential adjunctive treatment.20 Other treat-
ment options include zonisamide, a ketogenic diet, vagus nerve 
stimulation, or corpus callostomy.15,19
Due to the limited success of treatments for LGS, there 
is still a great demand for novel medications to manage this 
syndrome. An ideal medication would be effective in reducing 
the multiple seizure types associated with LGS, have a toler-
able side effect profile, and have limited drug–drug interactions 
with other AEDs.
The antiepileptic efficacy and tolerability of rufinamide was 
established in a clinical trial which led the United States Food 
and Drug Administration (FDA) to grant it orphan drug status 
in 2004. Rufinamide then received FDA approval in early 2009 
for adjunctive treatment of seizures associated with LGS in 
patients four years and older, as well as for adjunctive treatment 
of partial seizures in adults and adolescents. The purpose of this 
review is to analyze the current literature describing rufinamide 
use for the treatment of LGS.
Methods
A PubMed search was conducted by the authors for 
available studies limited to the terms “rufinamide” and 
  “Lennox-Gastaut syndrome”. Study population were 
evaluated for pediatrics and review article references were 
compared to search results.
Rufinamide
Rufinamide [1-(2,6-difluoro-phenyl)methyl-1H-1,2, 
3-  triazole-4-carboxamide], Banzel® (Eisai Co., Woodcliff 
Lake, NJ) is a third-generation AED with a triazole structure 
that has some similarity to lamotrigine.21 It mainly acts by 
prolonging the inactive state of sodium channels, inhibiting 
the firing of sodium-dependent action potentials.22
Pharmacokinetics/pharmacodynamics
Rufinamide is a lipophilic compound manufactured as 
200 mg and 400 mg coated tablets.23 A suspension is not 
currently available; however, a study of extemporaneously 
compounded suspensions of rufinamide (40 mg/mL) in a 
1:1 mixture of Ora-Plus® and Ora-Sweet® or Ora-Sweet SF® 
were found to be stable for at least 90 days.24
Rufinamide is not soluble in water and dissolves poorly in 
gastric contents. In a study of three healthy adult volunteers, 
a 600 mg oral dose was extensively absorbed ($85%).25 
Absorption is believed to be dissolution rate-limited and 
takes place in the small bowel.26 The maximum plasma 
concentration (mean) was reached within 6.6 hours after a 
single 400 mg dose.27 In three studies analyzing the influence 
of food on absorption in healthy adult subjects, taking rufin-
amide within one hour from mealtimes did not significantly 
affect plasma concentrations. However, bioavailability is 
significantly increased with administration after a high-fat 
meal versus administration after prolonged fasting. Prolonged 
fasting may decrease plasma levels and decrease seizure 
protection.26 Administration with food is recommended .23
Rufinamide is approximately 34% bound to plasma 
proteins.26 It is extensively metabolized to a carboxylic acid 
derivative (CGP 47292) and to glucuronide conjugates of 
CGP 47292. Very small amounts of the parent drug are found 
in the urine and feces. About 85% of the drug is eliminated 
renally. Rufinamide is not believed to be metabolized via the 
cytochrome P450 system.27,28 It displays monoexponential 
elimination, with a mean half-life of about nine hours in 
adults.27
A population analysis in 117 children (4–11 years) 
and 99 adolescents (12–17 years) determined that the 
  pharmacokinetics of rufinamide were similar to those seen 
in adult   studies.23 In a pharmacokinetic study of 129 adults 
and children with LGS, a decrease in bioavailability was 
observed with higher doses in the children. Clearance is 
also   proportional to body surface area; therefore, children Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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display higher steady-state concentrations and lower clear-
ance compared with adolescents or adults.29
Rufinamide has a low potential for drug–drug interactions 
due to its lack of protein binding and metabolism indepen-
dent of the cytochrome P450 system. This lack of significant 
drug interactions has been demonstrated clinically through a 
pharmacokinetic analysis using data from five double-blind 
studies in adults and children.30 Rufinamide was coadminis-
tered with carbamazepine (n = 903), valproic acid (n = 588), 
lamotrigine (n = 200), phenytoin (n = 299), phenobarbital 
(n = 149), and topiramate (n = 69). Rufinamide did not affect 
the clearance of topiramate or valproate, but increased the 
clearance of carbamazepine and lamotrigine, and decreased 
clearance of phenobarbital and phenytoin. However, these 
interactions were not considered clinically significant.30 
Another study demonstrated that rufinamide concentrations 
increased with concomitant valproate by 40% and 11% in 
children and adults, respectively. Therefore, dose reduction 
may be required with the initiation or withdrawal of concomi-
tant valproate.29 Rufinamide also resulted in a small increase 
in the clearance of the oral contraceptive Ortho-Novum® 
(ethinyl estradiol and norethindrone); however, the clinical 
significance of this interaction has not been elucidated.31
Safety
In a randomized, double-blind, placebo-controlled trial of 
rufinamide in 138 children and adults with LGS, the majority 
of reported adverse effects were similar between placebo and 
rufinamide at a dose of 45 mg/kg. There were significant dif-
ferences in somnolence (24.3% with rufinamide versus 12.5% 
with placebo) and vomiting (21.6% with rufinamide versus 
6.3% with placebo).14 Cognitive or psychiatric adverse events 
occurred in a lower percentage of patients taking rufinamide 
(17.6%) versus placebo (23.4%).14 Polytherapy increased 
the risk of adverse effects. During the extension phase of 
this trial, a total of 113 (91.1%) patients experienced an 
adverse effect. The most commonly reported adverse effects 
were vomiting (30.6%), pyrexia (25.8%), upper respiratory 
tract infection (21.8%), and somnolence (21%). A total of 
82 patients discontinued the medication prematurely, 9.7% 
due to adverse effects.32 The relationship between serum drug 
concentrations and adverse effects has also been analyzed 
in 1398 patients from both controlled and clinical studies. 
The most common adverse effects reported in controlled, 
  double-blind pediatric studies were dizziness (13%), fatigue 
(17%), nausea (9%), vomiting (7%), diplopia (6%), and 
somnolence (7%).26,33 Adverse effects were reported in a 
slightly higher percentage of adults (versus children), those 
with increased body weight, and in females. Increasing 
rufinamide plasma concentrations was also associated with 
an increase in adverse effects.33
A pooled analysis of seven clinical studies examined 
the incidence of adverse events specifically in the pediatric 
population (212 rufinamide-treated pediatric patients aged 
3–16 years, 197 placebo-treated patients aged 4–17 years, and 
391 patients in both double-blind or open-label extensions).34 
Overall, for all studies, 391 patients received an average dose 
of 41.67 mg/kg/day for 12–24 months. The most commonly 
reported adverse events were vomiting (26.3%), headache 
(22.5%), and pyrexia (18.7%).34 The most common serious 
adverse effects that occurred in more than one patient were 
aggravated seizures (2.8%), status epilepticus (2%), pneu-
monia (2%), and vomiting (1.5%). Discontinuation of treat-
ment occurred in 12.5% due to adverse effects. Five possible 
cases of AED hypersensitivity syndrome was discovered 
retrospectively in children younger than 12 years and within 
the first four weeks of treatment. In the double-blind trials 
alone, the median dose of rufinamide was 41.96 mg/kg/day 
for an average duration of three months. The most common 
adverse events reported (rufinamide versus placebo) were 
somnolence (17% versus 8.1%), vomiting (16.5% versus 
7.1%), and headache (16% versus 8.1%). Clinically relevant 
decreases in weight ($7%) were seen only in the rufinamide 
group (11/188, 5.9%) versus an increased incidence of weight 
gain observed in the placebo group (15/178, 8.4%). The 
rates of psychiatric adverse events that occurred between 
rufinamide and placebo were comparable, at 10.4% versus 
14.2%, respectively. Only one patient exhibited QT prolon-
gation and another exhibited electrocardiographic changes 
(exact change not specified).
In 18 healthy volunteers treated for 18 days with 
  rufinamide, dose-dependent QT interval decreases were 
reported.35 Rufinamide is therefore contraindicated in patients 
with a short QT interval due to risk of short QT syndrome 
(syncope, ventricular arrhythmia, possible sudden death).35 
Obtaining an electrocardiogram prior to initiating rufinamide 
would be prudent.
Efficacy in Lennox–Gastaut 
syndrome
Several trials have evaluated the effectiveness of rufinamide 
as an adjunctive treatment in LGS (see Table 1). The effi-
cacy of rufinamide as an adjunctive therapy for LGS was 
evaluated in a multicenter, randomized, placebo-controlled, 
parallel-group study in 138 patients aged 4–37 (mean 14) 
years of age.14 This study included a 12-week, double-blind Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Table 1 Trials of rufinamide for Lennox–Gastaut syndrome in pediatric patients
Study Population Design Results
Glauser et al14 138 patients  
Age 4–37 years  
Mean age 14.1 years  
Patients diagnosed with LGS, having  
$90 seizures in month prior to entry,  
and receiving stable treatment with  
1–3 concomitant AeDs
12-week, randomized, double-blind,  
placebo-controlled, parallel-group 
Subjects randomized to rufinamide  
up to 45 mg/kg/day (14 days titration)  
or placebo in addition to other AeDs
Median percent change in total 
seizure frequency per 28 days 
versus placebo: -32.7 versus -11.7, 
P = 0.0015 
Median percent change in tonic–
atonic seizure frequency per  
28 days versus placebo: -42.5 versus 
1.4, P , 0.0001 
improvement in seizure severity from 
parent/guardian global evaluation 
versus placebo: 53.4 versus 30.6, 
P = 0.0041 
Most common adverse effects were 
somnolence (24.3% versus 12.5%), 
vomiting (21.6% versus 6.3%), pyrexia 
(13.5% versus 17.2%), and diarrhea 
(5.4% versus 10.9%)  
Six discontinuations due to adverse 
events (3 vomiting, 
2 somnolence, 2 rash)
Glauser et al32 124 patients from previous study 
treated for a median of 432 days  
at 10–45 mg/kg/day  
Continued to meet all relevant  
inclusion/exclusion criteria  
from blinded study
Open-label extension phase  
14-day conversion period
There was a decrease in seizure 
frequency observed at all time points 
up to 3 years. Overall 50% response 
rate was 36.9%, with a 44.4% 
reduction in tonic–atonic seizures. 
These reductions were consistent 
over time. in approximately 50% 
of patients, the total daily dose of 
concomitant AeDs was decreased 
over 30 months of adjunctive 
treatment. 113 patients (91.1%) 
experienced an adverse effect;  
12 patients discontinued rufinamide 
due to adverse effects.
Kluger et al36 45 children and 15 adults  
(34 males, average age 14.5 years)  
taking concomitant antiepileptics
12-week, observational, retrospective  
data collection from eight epilepsy  
centers in Germany and Austria 
initial dosing/titration at the discretion  
of the physician, most started out at  
10 mg/kg/day
The mean final dose of rufinamide 
was 35.6 mg/kg/day. in the analysis 
of a subgroup of 31 patients with 
LGS, 54.8% (17/31) had a response 
rate, defined as a greater than 50% 
reduction in seizure frequency. Four 
patients were seizure-free.  
35 (58.3%) patients in all subgroups 
experienced at least one adverse 
event. Mild fatigue, vomiting, and 
anorexia were observed in 10%–18% 
of patients. No serious adverse 
events were reported.   A total of 
eight patients (13.3%) discontinued 
rufinamide during the three-month 
observation period (four due to 
adverse events).
phase followed by an open-label extension phase. Patients 
were randomized to placebo or twice-daily oral rufinamide 
titrated over 7 to 14 days to a daily target dose of 45 mg/kg 
in addition to their maintenance regimen. Of note, this 
trial set a detectable level of significance at 0.025. The two 
groups, placebo (n = 64) and rufinamide (n = 74), were 
equally   distributed demographically except for a slightly 
higher age and weight in the rufinamide group. Valproic 
acid,   lamotrigine, and topiramate were the most common 
concomitant   medications. Rufinamide serum concentrations Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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ranged from 4.95 to 48.15 µg/mL. The median reduction 
from baseline in the frequency of drop attacks per 28 days 
was significantly greater for rufinamide versus placebo 
(-42.5% versus +1.4%, P , 0.0001). Absence seizures 
showed a statistically significant decrease as well. The 
median reduction from baseline in frequency of all seizures 
was also significantly greater for study medication versus 
placebo (-32.7% versus -11.7%, P = 0.0015). These results 
were associated with a greater proportion of responders 
(patients achieving $50% reduction in seizures per 28-day 
period) for rufinamide versus placebo. The responder rate for 
total seizures was 31.1% versus 10.9% and for drop attacks 
was 42.5% versus 16.7% for rufinamide versus placebo, 
respectively. No patients were determined to be seizure-free 
during the study. However, 4.1% of patients demonstrated 
a 100% reduction in tonic–atonic seizures. A significant 
difference related to the parent/guardian global evaluation 
of the patient’s condition at the end of the study was not 
demonstrated either. There were no significant differences 
compared with placebo in the incidence of adverse events, 
apart from somnolence and vomiting, which was higher in 
the rufinamide group.
Following completion of this study, 123 patients (includ-
ing 74 males) entered the open-label, treatment-extension 
phase with a median dose of 1800 mg/day for a median dura-
tion of 432 days.32 Sixty percent of patients were treated for 
more than 18 months, 40% for more than two years, and 12% 
for three years or longer. Approximately half of the patients 
decreased their total daily dose of concomitant AEDs dur-
ing 30 months of adjunctive therapy with rufinamide. The 
reduction in median total seizure frequency was maintained, 
with some improvement noted in patients who continued 
treatment for up to three years. The responder rate for all 
seizures was also maintained, with 36.9% of patients having a 
50% decrease in seizure activity during the open-label phase. 
In addition, 21.3% of patients achieved a $75% reduction 
in overall total seizures, with 29.1% of patients achieving 
a $75% reduction in tonic–atonic seizures.
The long-term results of rufinamide in an open-label 
extension trial (trial presented above) were also published 
by the same research group.36 Kluger et al observed patients 
from 10 to 1149 days, with a median of 432 days. After study 
termination had occurred (44 months), 33.9% of patients 
were still receiving rufinamide, whereas 66.1% had dis-
continued due to various reasons, including unsatisfactory 
therapeutic response (n = 51), adverse events (n = 12), or 
other unspecified reasons (n = 19). Notably, patients who 
had been   receiving placebo (n = 59) during the double-
blind treatment phase went from a 1.5% decrease in total 
seizure frequency to a 22% median reduction in total seizure 
  frequency after two weeks on rufinamide. During the last 
12 months of rufinamide treatment, response rates ($50%) 
for total seizures and for tonic–atonic seizures were 41% 
and 47.9%, respectively. Eight patients (6.8%) achieved 
seizure freedom within the last 12 months of rufinamide 
treatment. More serious adverse events were reported during 
the extension study (13.7%) compared with the double-blind 
study (2.7%). Serious adverse events reported and sus-
pected to be treatment-related included rash, constipation, 
esophagitis, decreased weight, gastritis, anorexia, vomiting, 
lethargy, and status epilepticus. This trial demonstrated 
that rufinamide was able to maintain seizure control over 
the long term.36
A 12-week, retrospective, observational study conducted 
in Europe by Kluger et al included 45 children and 15 adults 
(mean age 14.5 years) with various refractory epilepsy syn-
dromes.37 Thirty-one of the study patients were diagnosed 
with LGS. Researchers determined response rates by compar-
ing frequency of seizures during the first four-week period 
of the trial before drug initiation versus seizure frequency 
with rufinamide during the last four weeks of observation. 
Seventeen patients with LGS responded to rufinamide 
(54.8%), with eight patients exhibiting a 50%–75% seizure 
reduction, five a 75%–99% reduction, and four achieving 
complete freedom from seizures during the last four weeks 
of observation.37
Other studies
A three-year cost-efficacy analysis of rufinamide versus 
lamotrigine and topiramate for children with LGS was con-
ducted in the United Kingdom based on the current published 
literature.38 This study looked at the relationship between 
costs and quality of life years. Quality of life was based on 
response rates to each medication, as well as tolerability. 
Rufinamide had the highest cumulative cost compared with 
topiramate and lamotrigine. However, the authors concluded 
that the extra expense for rufinamide was warranted if a 
patient’s quality of life was improved, because LGS can be 
such a devastating condition.
Currently, there are no direct comparisons of trial data 
for rufinamide versus other adjunctive therapies for LGS. In 
addition, a Cochrane review of LGS treatment was unable to 
compare rufinamide effectively as an adjunctive therapy to 
other AEDs due to a lack of direct comparison trials, as well 
as differences in trial designs and population.39 This review 
did suggest, however, that one specific medication has not Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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been shown to be more effective than another and, thus, 
rufinamide, lamotrigine, topiramate, and felbamate should 
all be considered as an adjunctive treatment for LGS. 
Patient-specific issues may assist with guiding selection of 
medication. Rufinamide may be a more efficacious option 
compared with current alternatives due to the fact that the 
patients included in the relevant clinical studies may have 
had more refractory forms of LGS and were already taking 
multiple AEDs.
Conclusion
The available literature to date examining rufinamide, a 
third-generation AED, for the treatment of LGS suggests 
that it is both a safe and effective adjunctive treatment 
option for patients who are refractory to therapy with mul-
tiple AEDs. The FDA-approved pediatric dosage is up to 
45 mg/kg or 3200 mg/day divided into two doses, which 
is consistent with effective dosages from the trials. Tablets 
may be crushed for pediatric administration and the dose 
should be administered with a meal to increase absorp-
tion.23 Cost may be a challenge due to the availability of 
only brand-name dosage forms on the market. However, 
a pharmacoeconomic analysis38   suggests that increased 
quality of life with rufinamide outweighs its increased cost 
compared with alternatives.
The most common adverse effects for rufinamide include 
somnolence, vomiting, dizziness, and fatigue, but these are 
relatively mild and typically do not warrant drug discontinu-
ation.33 Rufinamide is a worthwhile adjunctive treatment for 
LGS due to its relative lack of clinically significant drug inter-
actions and its acceptable adverse effect profile compared 
with older anticonvulsants. Additional studies are needed to 
further assess its short- and long-term efficacy and safety, 
as well as drug interactions. In addition, a direct comparison 
between rufinamide and alternative adjunctive treatments 
is warranted to assess its place in therapy. Rufinamide is a 
promising adjunctive agent for the treatment of pediatric LGS 
and may significantly decrease seizure frequency in patients 
who are refractory to other therapies.
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